Novo Nordisk A/S: Novo Nordisk increased operating profit by 32% in 2012

Novo Nordisk A/S: Novo Nordisk increased operating profit by 32% in 2012 
BAGSVAERD, DENMARK -- (Marketwire) -- 01/31/13 --  Sales growth of
18% driven by Victoza(R), NovoRapid(R) and Levemir(R) Sales increased
by 18% to 78.0 billion in Danish kroner and by 12% in local
currencies. 
*   Sales of modern insulins increased by 21% (15% in local
currencies). 
*   Sales of Victoza(R) increased by 58% (50% in local currencies). 
*   Sales in North America increased by 29% (19% in local
currencies). 
*   Sales in International Operations increased by 18% (16% in local
currencies). 
Reported operating profit increased by 32% to DKK 29.5 billion
including a 1.7
percentage points improvement in the gross margin.
Measured in local currencies,
operating profit increased by 20%. 
Company announcement No 8 / 2013:
http://hugin.info/2013/R/1674355/545183.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that:  
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Novo Nordisk A/S via Thomson Reuters ONE 
[HUG#1674355] 
CONTACTS FOR FURTHER INFORMATION
Media:
Mike Rulis
+45 4442 3573
mike@novonordisk.com 
Ken Inchausti (US)
+1 609 514 8316
kiau@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
+45 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard (US)
+1 609 786 4575
jlis@novonordisk.com
 
 
Press spacebar to pause and continue. Press esc to stop.